Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 295

1.

Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II-III and BIOFLOW II trials.

Hideo-Kajita A, Garcia-Garcia HM, Kolm P, Azizi V, Ozaki Y, Dan K, Ince H, Kische S, Abizaid A, Töelg R, Lemos PA, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Wijns W, Lefèvre T, Windecker S, Waksman R, Haude M; BIOFLOW-II, BIOSOLVE-II and BIOSOLVE-III investigators.

Int J Cardiol. 2019 Nov 6. pii: S0167-5273(19)33609-5. doi: 10.1016/j.ijcard.2019.11.003. [Epub ahead of print]

PMID:
31718825
2.

The Obesity Paradox Revisited: Body Mass Index and Long-Term Outcomes After PCI From a Large Pooled Patient-Level Database.

Wolny R, Maehara A, Liu Y, Zhang Z, Mintz GS, Redfors B, Madhavan MV, Smits PC, von Birgelen C, Serruys PW, Mehran R, Leon MB, Stone GW.

EuroIntervention. 2019 Oct 29. pii: EIJ-D-19-00467. doi: 10.4244/EIJ-D-19-00467. [Epub ahead of print]

3.

Three-year clinical outcome in all-comers with "silent" diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes study.

Ploumen EH, Buiten RA, Kok MM, Doggen CJM, van Houwelingen KG, Stoel MG, de Man FHAF, Hartmann M, Zocca P, Linssen GCM, Doelman C, Kant GD, von Birgelen C.

Catheter Cardiovasc Interv. 2019 Oct 17. doi: 10.1002/ccd.28536. [Epub ahead of print]

PMID:
31625262
4.

Ultrathin Strut Stents in Small Coronary Vessels-Are We There Yet?-Reply.

Buiten RA, Ploumen EH, von Birgelen C.

JAMA Cardiol. 2019 Oct 16. doi: 10.1001/jamacardio.2019.3915. [Epub ahead of print] No abstract available.

PMID:
31617861
5.

Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention.

Garcia-Garcia HM, McFadden EP, von Birgelen C, Rademaker-Havinga T, Spitzer E, Kleiman NS, Cohen DJ, Kennedy KF, Camenzind E, Mauri L, Steg PG, Wijns W, Silber S, van Es GA, Serruys PW, Windecker S, Cutlip D, Vranckx P.

JACC Cardiovasc Interv. 2019 Oct 14;12(19):1954-1962. doi: 10.1016/j.jcin.2019.07.014.

PMID:
31601389
6.

Superiority of biodegradable polymer sirolimus-eluting stents in STEMI.

von Birgelen C, Buiten RA.

Lancet. 2019 Oct 5;394(10205):1208-1210. doi: 10.1016/S0140-6736(19)31955-5. Epub 2019 Sep 2. No abstract available.

PMID:
31488367
7.

Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.

Buiten RA, Ploumen EH, Zocca P, Doggen CJM, Danse PW, Schotborgh CE, Scholte M, van Houwelingen KG, Stoel MG, Hartmann M, Tjon Joe Gin RM, Somi S, Linssen GCM, Kok MM, von Birgelen C.

JACC Cardiovasc Interv. 2019 Sep 9;12(17):1650-1660. doi: 10.1016/j.jcin.2019.04.054. Epub 2019 Aug 14.

PMID:
31422087
8.

BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: three-year clinical outcomes of the PIONEER trial.

Chang CC, Kogame N, Asano T, von Birgelen C, Sabaté M, Onuma Y, Serruys PW.

EuroIntervention. 2019 Jul 30. pii: EIJ-D-19-00566. doi: 10.4244/EIJ-D-19-00566. [Epub ahead of print] No abstract available.

9.

Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.

Baber U, Stefanini GG, Giustino G, Stone GW, Leon MB, Sartori S, Aquino M, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, von Birgelen C, Dangas GD, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.

Circ Cardiovasc Interv. 2019 Jul;12(7):e007734. doi: 10.1161/CIRCINTERVENTIONS.118.007734. Epub 2019 Jul 10.

PMID:
31288561
10.

Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.

Postma W, Fabris E, Van der Ent M, Hermanides R, Buszman P, Von Birgelen C C, Cook S, Wedel H, De Luca G, Delewi R, Zijlstra F, Kedhi E.

Catheter Cardiovasc Interv. 2019 Jul 3. doi: 10.1002/ccd.28376. [Epub ahead of print]

PMID:
31268629
11.

Temporal Changes in Coronary Hyperemic and Resting Hemodynamic Indices in Nonculprit Vessels of Patients With ST-Segment Elevation Myocardial Infarction.

van der Hoeven NW, Janssens GN, de Waard GA, Everaars H, Broyd CJ, Beijnink CWH, van de Ven PM, Nijveldt R, Cook CM, Petraco R, Ten Cate T, von Birgelen C, Escaned J, Davies JE, van Leeuwen MAH, van Royen N.

JAMA Cardiol. 2019 Jul 3. doi: 10.1001/jamacardio.2019.2138. [Epub ahead of print]

PMID:
31268466
12.

Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention.

Brener SJ, Leon MB, Serruys PW, Smits PC, von Birgelen C, Mehran R, Kirtane AJ, Witzenbichler B, Rinaldi MJ, Metzger DC, Mazzaferri EL Jr, Zhang Z, Stone GW; Collaborators.

EuroIntervention. 2019 Aug 9;15(6):e551-e557. doi: 10.4244/EIJ-D-19-00262.

13.

Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.

Buiten RA, Ploumen EH, Zocca P, Doggen CJM, van der Heijden LC, Kok MM, Danse PW, Schotborgh CE, Scholte M, de Man FHAF, Linssen GCM, von Birgelen C.

JAMA Cardiol. 2019 Jul 1;4(7):659-669. doi: 10.1001/jamacardio.2019.1776.

PMID:
31111862
14.

First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.

Hideo-Kajita A, Garcia-Garcia HM, Haude M, Joner M, Koolen J, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Teik LS, Escaned J, Azizi V, Kuku KO, Ozaki Y, Dan K, Waksman R.

Cardiovasc Revasc Med. 2019 May;20(5):392-398. doi: 10.1016/j.carrev.2019.02.019. Epub 2019 Feb 18.

PMID:
31079817
15.

Simultaneous evaluation of plaque stability and ischemic potential of coronary lesions in a fluid-structure interaction analysis.

Wu X, von Birgelen C, Zhang S, Ding D, Huang J, Tu S.

Int J Cardiovasc Imaging. 2019 Sep;35(9):1563-1572. doi: 10.1007/s10554-019-01611-y. Epub 2019 May 3.

PMID:
31053979
16.

Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.

Räber L, Yamaji K, Kelbæk H, Engstrøm T, Baumbach A, Roffi M, von Birgelen C, Taniwaki M, Moschovitis A, Zaugg S, Ostojic M, Pedrazzini G, Karagiannis-Voules DA, Lüscher TF, Kornowski R, Tüller D, Vukcevic V, Heg D, Windecker S.

Eur Heart J. 2019 Jun 21;40(24):1909-1919. doi: 10.1093/eurheartj/ehz074.

PMID:
30851032
17.

Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: 3-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.

Haude M, Ince H, Tölg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Eeckhout E, Garcia-Garcia HM, Waksman R.

EuroIntervention. 2019 Feb 26. pii: EIJ-D-18-01000. doi: 10.4244/EIJ-D-18-01000. [Epub ahead of print]

18.

Reply to the letter to the editor regarding the article "Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population".

Kok MM, Sattar N, von Birgelen C.

EuroIntervention. 2019 Feb 8;14(15):e1621-e1622. doi: 10.4244/EIJ-D-18-00235R. No abstract available.

19.

Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial).

Ozaki Y, Garcia-Garcia HM, Hideo-Kajita A, Kuku KO, Haude M, Ince H, Abizaid A, Tölg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Escaned J, Waksman R.

Am J Cardiol. 2019 Apr 1;123(7):1044-1051. doi: 10.1016/j.amjcard.2018.12.029. Epub 2019 Jan 4.

PMID:
30683424
20.

Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis.

Ozaki Y, Garcia-Garcia HM, Hideo-Kajita A, Kuku KO, Haude M, Ince H, Abizaid A, Tölg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Escaned J, Dijkstra J, Waksman R.

Eur Heart J Cardiovasc Imaging. 2019 Aug 1;20(8):916-924. doi: 10.1093/ehjci/jey210.

PMID:
30590578
21.

Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.

van Leeuwen MAH, van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Ten Cate TJF, Piek JJ, von Birgelen C, Escaned J, Valgimigli M, Diletti R, Riksen NP, van Mieghem NM, Nijveldt R, van Royen N.

Circulation. 2019 Jan 29;139(5):636-646. doi: 10.1161/CIRCULATIONAHA.118.035931.

PMID:
30586720
22.

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F.

BMJ. 2018 Oct 2;363:k3793. doi: 10.1136/bmj.k3793.

23.

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.

von Birgelen C, Zocca P, Buiten RA, Jessurun GAJ, Schotborgh CE, Roguin A, Danse PW, Benit E, Aminian A, van Houwelingen KG, Anthonio RL, Stoel MG, Somi S, Hartmann M, Linssen GCM, Doggen CJM, Kok MM.

Lancet. 2018 Oct 6;392(10154):1235-1245. doi: 10.1016/S0140-6736(18)32001-4. Epub 2018 Sep 22.

PMID:
30253879
24.

Is the proximal left anterior descending coronary artery segment justifiably considered as the last frontier for stenting?

Roguin A, Solomonica A, von Birgelen C.

EuroIntervention. 2018 Sep 20;14(7):729-731. doi: 10.4244/EIJV14I7A127. No abstract available.

25.

Late clinical outcome of stent trials: a matter of life or death?

von Birgelen C, Zocca P.

Lancet. 2018 Sep 1;392(10149):713-714. doi: 10.1016/S0140-6736(18)31860-9. Epub 2018 Aug 28. No abstract available.

PMID:
30170847
26.

High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial.

Zocca P, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Linssen GCM, Doggen CJM, von Birgelen C.

Cardiovasc Drugs Ther. 2018 Dec;32(6):567-576. doi: 10.1007/s10557-018-6823-9.

27.

Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis.

Weernink MGM, Vaanholt MCW, Groothuis-Oudshoorn CGM, von Birgelen C, IJzerman MJ, van Til JA.

Am J Cardiovasc Drugs. 2018 Dec;18(6):493-502. doi: 10.1007/s40256-018-0293-0.

28.

Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials.

Vaanholt MCW, Kok MM, von Birgelen C, Weernink MGM, van Til JA.

Health Expect. 2018 Dec;21(6):1046-1055. doi: 10.1111/hex.12798. Epub 2018 Aug 14.

29.

Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III.

Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Barbato E, Garcia-Garcia HM, Waksman R; BIOSOLVE-II and III investigators.

Catheter Cardiovasc Interv. 2018 Dec 1;92(7):E502-E511. doi: 10.1002/ccd.27680. Epub 2018 Aug 5.

30.

Cardiovascular and Noncardiovascular Death After Percutaneous Coronary Intervention: Insights From 32 882 Patients Enrolled in 21 Randomized Trials.

Brener SJ, Tarantini G, Leon MB, Serruys PW, Smits PC, von Birgelen C, Crowley A, Ben-Yehuda O, Stone GW.

Circ Cardiovasc Interv. 2018 Jul;11(7):e006488. doi: 10.1161/CIRCINTERVENTIONS.118.006488.

PMID:
30006331
31.

Perceived advantages and disadvantages of oral anticoagulants, and the trade-offs patients make in choosing anticoagulant therapy and adhering to their drug regimen.

Vaanholt MCW, Weernink MGM, von Birgelen C, Groothuis-Oudshoorn CGM, IJzerman MJ, van Til JA.

Patient Educ Couns. 2018 Nov;101(11):1982-1989. doi: 10.1016/j.pec.2018.06.019. Epub 2018 Jun 30.

32.

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FHAF, Stoel MG, Louwerenburg JHW, Knottnerus IL, Linssen GCM, Doggen CJM, von Birgelen C.

Int J Cardiol. 2018 Oct 1;268:11-17. doi: 10.1016/j.ijcard.2018.03.116. Epub 2018 May 23.

33.

Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial.

Kok MM, Zocca P, Buiten RA, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Stoel MG, van Houwelingen G, Linssen GCM, Doggen CJM, von Birgelen C.

EuroIntervention. 2018 Oct 20;14(8):915-923. doi: 10.4244/EIJ-D-18-00336.

34.

Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients.

Palmerini T, Della Riva D, Biondi-Zoccai G, Leon MB, Serruys PW, Smits PC, von Birgelen C, Ben-Yehuda O, Généreux P, Bruno AG, Jenkins P, Stone GW.

JACC Cardiovasc Interv. 2018 May 14;11(9):892-902. doi: 10.1016/j.jcin.2018.01.277. Epub 2018 Apr 18.

35.

Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.

van der Heijden LC, Kok MM, Zocca P, Jessurun GAJ, Schotborgh CE, Roguin A, Benit E, Aminian A, Danse PW, Löwik MM, Linssen GCM, van der Palen J, Doggen CJM, von Birgelen C.

Am Heart J. 2018 Apr;198:25-32. doi: 10.1016/j.ahj.2017.12.011. Epub 2017 Dec 21.

36.

Serial assessment of endothelial function 1, 6, and 12 months after ST-elevation myocardial infarction.

Kandhai-Ragunath JJ, Doggen CJM, van der Heijden LC, Kok MM, Zocca P, de Wagenaar B, Doelman C, Jørstad HT, Peters RJG, von Birgelen C.

Heart Vessels. 2018 Sep;33(9):978-985. doi: 10.1007/s00380-018-1145-1. Epub 2018 Mar 14.

37.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031.

38.

Quantification of disturbed coronary flow by disturbed vorticity index and relation with fractional flow reserve.

Chu M, von Birgelen C, Li Y, Westra J, Yang J, Holm NR, Reiber JHC, Wijns W, Tu S.

Atherosclerosis. 2018 Jun;273:136-144. doi: 10.1016/j.atherosclerosis.2018.02.023. Epub 2018 Feb 16.

PMID:
29501225
39.

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

von Birgelen C, Kok MM, Sattar N, Zocca P, Doelman C, Kant GD, Löwik MM, van der Heijden LC, Sen H, van Houwelingen KG, Stoel MG, Louwerenburg JHW, Hartmann M, de Man FHAF, Linssen GCM, Doggen CJM, Tandjung K.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):448-459. doi: 10.1016/j.jcin.2017.10.038. Epub 2018 Feb 14.

40.

Assessment of superficial coronary vessel wall deformation and stress: validation of in silico models and human coronary arteries in vivo.

Wu X, von Birgelen C, Li Z, Zhang S, Huang J, Liang F, Li Y, Wijns W, Tu S.

Int J Cardiovasc Imaging. 2018 Jun;34(6):849-861. doi: 10.1007/s10554-018-1311-7. Epub 2018 Feb 3.

PMID:
29397475
41.

Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.

van der Heijden LC, Kok MM, Zocca P, Sen H, Löwik MM, Mariani S, de Man FHAF, Hartmann M, Stoel MG, van Houwelingen KG, Louwerenburg JHW, Linssen GCM, Doggen CJM, Grandjean JG, von Birgelen C.

J Am Heart Assoc. 2018 Jan 30;7(3). pii: e007212. doi: 10.1161/JAHA.117.007212.

42.

Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population.

Kok MM, von Birgelen C, Sattar N, Zocca P, Löwik MM, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Kant GD, Doelman C, Tjon Joe Gin M, Stoel MG, van Houwelingen G, Linssen GCM, IJzerman MJ, Doggen CJM, van der Heijden LC.

EuroIntervention. 2018 Oct 12;14(9):e1049-e1056. doi: 10.4244/EIJ-D-17-01067.

43.

Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative.

Chandrasekhar J, Baber U, Sartori S, Stefanini GG, Sarin M, Vogel B, Farhan S, Camenzind E, Leon MB, Stone GW, Serruys PW, Wijns W, Steg PG, Weisz G, Chieffo A, Kastrati A, Windecker S, Morice MC, Smits PC, von Birgelen C, Mikhail GW, Itchhaporia D, Mehta L, Kim HS, Valgimigli M, Jeger RV, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R.

JACC Cardiovasc Interv. 2018 Jan 8;11(1):53-65. doi: 10.1016/j.jcin.2017.11.020.

44.

In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.

Garcia-Garcia HM, Haude M, Kuku K, Hideo-Kajita A, Ince H, Abizaid A, Tölg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Escaned J, Dijkstra J, Waksman R.

Int J Cardiol. 2018 Mar 15;255:22-28. doi: 10.1016/j.ijcard.2017.12.053. Epub 2017 Dec 28.

PMID:
29292064
45.

Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials.

Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S, Sorrentino S, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, Valgimigli M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Dangas GD, Morice MC, Mehran R.

JACC Cardiovasc Interv. 2018 Jan 8;11(1):68-76. doi: 10.1016/j.jcin.2017.06.060. Epub 2017 Dec 13.

46.

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.

Zocca P, van der Heijden LC, Kok MM, Löwik MM, Hartmann M, Stoel MG, Louwerenburg JW, de Man FHAF, Linssen GCM, Knottnerus IL, Doggen CJM, van Houwelingen KG, von Birgelen C.

EuroIntervention. 2017 Nov 20;13(10):1168-1176. doi: 10.4244/EIJ-D-17-00634.

47.

Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy.

Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Íñiguez-Romo A, Janssens L, Smits PC, Wykrzykowska JJ, Ribeiro VG, Pereira H, da Silva PC, Piek JJ, Reiber JHC, von Birgelen C, Sabaté M, Onuma Y, Serruys PW.

EuroIntervention. 2018 Aug 3;14(5):e570-e579. doi: 10.4244/EIJ-D-17-00461.

48.

First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial.

von Birgelen C, Asano T, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Iñiguez A, Janssens L, Smits PC, Wykrzykowska JJ, Ribeiro VG, Pereira H, da Silva PC, Piek JJ, Onuma Y, Serruys PW, Sabaté M.

EuroIntervention. 2018 Apr 20;13(17):2026-2035. doi: 10.4244/EIJ-D-17-00462.

49.

Reply to Letter to the Editor entitled: "Bioresorbable stent thrombosis, lactic acid release and Kounis syndrome".

von Birgelen C, van der Heijden LC, Mukete BN.

Int J Cardiol. 2017 Nov 15;247:16. doi: 10.1016/j.ijcard.2017.06.021. No abstract available.

PMID:
28916056
50.

Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis.

Kalkman DN, Kok MM, van der Heijden LC, Woudstra P, Beijk MAM, Tijssen JGP, von Birgelen C, de Winter RJ.

EuroIntervention. 2017 Nov 20;13(10):1202-1209. doi: 10.4244/EIJ-D-17-00301.

Supplemental Content

Loading ...
Support Center